Company profilePharmaceutical#320 of 1,318 in Pakistan✓ No DRAP alerts

FAAS Pharmaceuticals (Pvt)Ltd

Pharmaceutical company · 55 brands · 55 molecules

Ranked #20 of 55 companies in Antidiarrheals, Intestinal Antiinflammatory/Antiinfective

55 registered products 33 pharmaceutical brands 55 distinct molecules 0 DRAP alerts

Company overview

55
registered products
33
pharmaceutical brands
55
distinct molecules
4
therapeutic classes
0
DRAP alerts

FAAS Pharmaceuticals (Pvt)Ltd is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 55 product registrations across 55 distinct molecules. Its portfolio is concentrated in Antidiarrheals, Intestinal Antiinflammatory/Antiinfective and Antihistamines For Systemic Use. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by FAAS

37 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Antidiarrheals, Intestinal Antiinflammatory/Antiinfective 1

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

37
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202637

Top molecules by brand count

Rivaroxaban4 brands
Artemether4 brands
Azithromycin4 brands
Omeprazole3 brands
Linezolid3 brands
Levofloxacin2 brands
Ceftriaxone2 brands
Entecavir2 brands

Therapeutic classes

Antidiarrheals, Intestinal Antiinflammatory/Antiinfective · 2Antihistamines For Systemic Use · 1Enzymes To Treat Inflammatory Condition · 1Antianemic, Iron Preparations · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official62 products · Rs 53.06 – Rs 21,608.14
Median across source: Rs 602.82

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

NEUTRO PHARMA (PVT) LTD. holds 104 molecules not in this portfolio
AcyclovirAlbendazoleAmikacinAnastrazoleAnastrozoleAntimony
GETZ PHARMA PAKISTAN (PVT) LTD. holds 252 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole
SHAIGAN PHARMACEUTICALS (PVT) LTD. holds 120 molecules not in this portfolio
AlbendazoleAmikacinAmlodipineAmlodipine BasylateAspirinBetamethasone

Get the full profile for FAAS

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.